{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:16:35Z","timestamp":1793412995006,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","award":["Study support, medical writing support"],"award-info":[{"award-number":["Study support, medical writing support"]}],"id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","award":["Study support, medical writing support"],"award-info":[{"award-number":["Study support, medical writing support"]}],"id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","award":["Study support, medical writing support"],"award-info":[{"award-number":["Study support, medical writing support"]}],"id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","award":["Study support, medical writing support"],"award-info":[{"award-number":["Study support, medical writing support"]}],"id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","award":["Study support, medical writing support"],"award-info":[{"award-number":["Study support, medical writing support"]}],"id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","award":["Study support, medical writing support"],"award-info":[{"award-number":["Study support, medical writing support"]}],"id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","award":["Study support, medical writing support"],"award-info":[{"award-number":["Study support, medical writing support"]}],"id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","award":["Study support, medical writing support"],"award-info":[{"award-number":["Study support, medical writing support"]}],"id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30-EY026877"],"award-info":[{"award-number":["P30-EY026877"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"DOI":"10.1186\/s12886-024-03797-9","type":"journal-article","created":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T09:29:19Z","timestamp":1735550959000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["How intravitreal anti-vascular endothelial growth factor initial dosing impacts patient outcomes in diabetic macular oedema"],"prefix":"10.1186","volume":"24","author":[{"given":"Rishi P.","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Tabano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanche L.","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"LaPrise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore","family":"Leng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunice","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan","family":"Hatfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Garmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,30]]},"reference":[{"issue":"4","key":"3797_CR1","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1016\/j.survophthal.2022.01.009","volume":"67","author":"JHB Im","year":"2022","unstructured":"Im JHB, Jin YP, Chow R, Yan P. Prevalence of diabetic macular edema based on optical coherence tomography in people with diabetes: a systematic review and meta-analysis. Surv Ophthalmol. 2022;67(4):1244\u201351. https:\/\/doi.org\/10.1016\/j.survophthal.2022.01.009.","journal-title":"Surv Ophthalmol"},{"key":"3797_CR2","doi-asserted-by":"publisher","unstructured":"Zhang J, Zhang J, Zhang C, et al. Diabetic macular edema: current understanding, molecular mechanisms and therapeutic implications. Cells. 2022;25(21):3362. https:\/\/doi.org\/10.3390\/cells11213362.","DOI":"10.3390\/cells11213362"},{"issue":"5","key":"3797_CR3","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.oret.2021.12.019","volume":"6","author":"M Reibaldi","year":"2022","unstructured":"Reibaldi M, Fallico M, Avitabile T, et al. Frequency of intravitreal anti-VEGF injections and risk of death: a systematic review with meta-analysis. Ophthalmol Retina. 2022;6(5):369\u201376. https:\/\/doi.org\/10.1016\/j.oret.2021.12.019.","journal-title":"Ophthalmol Retina"},{"issue":"12","key":"3797_CR4","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.4103\/ijo.IJO_1240_18","volume":"66","author":"DJ Browning","year":"2018","unstructured":"Browning DJ, Stewart MW, Lee C. Diabetic macular edema: evidence-based management. Indian J Ophthalmol. 2018;66(12):1736\u201350. https:\/\/doi.org\/10.4103\/ijo.IJO_1240_18.","journal-title":"Indian J Ophthalmol"},{"issue":"2","key":"3797_CR5","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1136\/bjophthalmol-2020-315933","volume":"105","author":"TA Ciulla","year":"2021","unstructured":"Ciulla TA, Pollack JS, Williams DF. Visual acuity outcomes and anti-VEGF therapy intensity in diabetic macular oedema: a real-world analysis of 28 658 patient eyes. Br J Ophthalmol. 2021;105(2):216\u201321. https:\/\/doi.org\/10.1136\/bjophthalmol-2020-315933.","journal-title":"Br J Ophthalmol"},{"issue":"12","key":"3797_CR6","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1136\/bjophthalmol-2016-308388","volume":"100","author":"M Ashraf","year":"2016","unstructured":"Ashraf M, Souka A, Adelman R. Predicting outcomes to anti-vascular endothelial growth factor (VEGF) therapy in diabetic macular oedema: a review of the literature. Br J Ophthalmol. 2016;100(12):1596\u2013604. https:\/\/doi.org\/10.1136\/bjophthalmol-2016-308388.","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"3797_CR7","doi-asserted-by":"publisher","first-page":"e14746","DOI":"10.1111\/dme.14746","volume":"39","author":"T Peto","year":"2022","unstructured":"Peto T, Akerele T, Sagkriotis A, Zappacosta S, Clemens A, Chakravarthy U. Treatment patterns and persistence rates with anti-vascular endothelial growth factor treatment for diabetic macular oedema in the UK: a real-world study. Diabet Med. 2022;39(4):e14746. https:\/\/doi.org\/10.1111\/dme.14746.","journal-title":"Diabet Med"},{"key":"3797_CR8","doi-asserted-by":"publisher","unstructured":"Skelly A, Bezlyak V, Liew G, Kap E, Sagkriotis A. Treat and extend treatment interval patterns with anti-VEGF therapy in nAMD patients. Vision (Basel). 2019;26(3):41. https:\/\/doi.org\/10.3390\/vision3030041.","DOI":"10.3390\/vision3030041"},{"issue":"8","key":"3797_CR9","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1038\/eye.2013.93","volume":"27","author":"G Menon","year":"2013","unstructured":"Menon G, Chandran M, Sivaprasad S, Chavan R, Narendran N, Yang Y. Is it necessary to use three mandatory loading doses when commencing therapy for neovascular age-related macular degeneration using bevacizumab? (BeMOc Trial). Eye (Lond). 2013;27(8):959\u201363. https:\/\/doi.org\/10.1038\/eye.2013.93.","journal-title":"Eye (London England)"},{"key":"3797_CR10","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s40942-016-0041-z","volume":"2","author":"F Ziemssen","year":"2016","unstructured":"Ziemssen F, Schlottman PG, Lim JI, Agostini H, Lang GE, Bandello F. Initiation of intravitreal aflibercept injection treatment in patients with diabetic macular edema: a review of VIVID-DME and VISTA-DME data. Int J Retina Vitreous. 2016;2:16. https:\/\/doi.org\/10.1186\/s40942-016-0041-z.","journal-title":"Int J Retina Vitreous"},{"issue":"1","key":"3797_CR11","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12886-017-0401-y","volume":"19","author":"F Ziemssen","year":"2017","unstructured":"Ziemssen F, Feltgen N, Holz FG, et al. Demographics of patients receiving intravitreal anti-VEGF treatment in real-world practice: healthcare research data versus randomized controlled trials. BMC Ophthalmol. 2017;19(1):7. https:\/\/doi.org\/10.1186\/s12886-017-0401-y.","journal-title":"BMC Ophthalmol"},{"issue":"3","key":"3797_CR12","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.ophtha.2019.10.019","volume":"127","author":"RA Cantrell","year":"2020","unstructured":"Cantrell RA, Lum F, Chia Y, et al. Treatment patterns for diabetic macular edema: an intelligent research in sight (IRIS\u00ae) registry analysis. Ophthalmol. 2020;127(3):427\u20139. https:\/\/doi.org\/10.1016\/j.ophtha.2019.10.019.","journal-title":"Ophthalmol"},{"issue":"8","key":"3797_CR13","first-page":"603","volume":"62","author":"I Kozak","year":"2021","unstructured":"Kozak I, Centeno J. The effect of anti-VEGF injection loading dose in diabetic macular edema as measured by hand-held ERG system [Presented at ARVO annual meeting 2021]. Invest Ophthalmol Vis Sci. 2021;62(8):603.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"3797_CR14","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1159\/000495623","volume":"241","author":"P Schwarzer","year":"2019","unstructured":"Schwarzer P, Ebneter A, Munk M, Wolf S, Zinkernagel MS. One-year results of using a treat-and-extend regimen without a loading phase with anti-VEGF agents in patients with treatment-naive diabetic macular edema. Ophthalmologica. 2019;241(4):220\u20135. https:\/\/doi.org\/10.1159\/000495623.","journal-title":"Ophthalmologica"},{"key":"3797_CR15","doi-asserted-by":"publisher","first-page":"102282","DOI":"10.1016\/j.pdpdt.2021.102282","volume":"34","author":"N A\u015fikgarip","year":"2021","unstructured":"A\u015fikgarip N, Yenerel NM. Comparison of the effects of intravitreal ranibizumab and aflibercept on retinal vessel diameters in patients with diabetic macular edema. Photodiagnosis Photodyn Ther. 2021;34:102282. https:\/\/doi.org\/10.1016\/j.pdpdt.2021.102282.","journal-title":"Photodiagnosis Photodyn Ther"},{"key":"3797_CR16","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.2147\/opth.S374763","volume":"16","author":"JI Fern\u00e1ndez-Vigo","year":"2022","unstructured":"Fern\u00e1ndez-Vigo JI, Contreras I, Crespo MJ, et al. Expert panel consensus for addressing anti-VEGF treatment challenges of diabetic macular edema in Spain. Clin Ophthalmol. 2022;16:3097\u2013106. https:\/\/doi.org\/10.2147\/opth.S374763.","journal-title":"Clin Ophthalmol"},{"issue":"7","key":"3797_CR17","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1097\/IAE.0b013e3181d87e04","volume":"30","author":"NZ Gregori","year":"2010","unstructured":"Gregori NZ, Feuer W, Rosenfeld PJ. Novel method for analyzing Snellen visual acuity measurements. Retina. 2010;30(7):1046\u201350. https:\/\/doi.org\/10.1097\/IAE.0b013e3181d87e04.","journal-title":"Retina"},{"issue":"2","key":"3797_CR18","doi-asserted-by":"publisher","first-page":"217","DOI":"10.2307\/2983604","volume":"1","author":"F Yates","year":"2018","unstructured":"Yates F. Contingency tables involving small numbers and the \u03c72 test. Supplement J Royal Stat Soc. 2018;1(2):217\u201335. https:\/\/doi.org\/10.2307\/2983604.","journal-title":"Supplement J Royal Stat Soc"},{"issue":"4","key":"3797_CR19","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1177\/0004563221992088","volume":"58","author":"RM West","year":"2021","unstructured":"West RM. Best practice in statistics: use the Welch t-test when testing the difference between two groups. Ann Clin Biochem. 2021;58(4):267\u20139. https:\/\/doi.org\/10.1177\/0004563221992088.","journal-title":"Ann Clin Biochem"},{"issue":"4","key":"3797_CR20","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1002\/sim.3776","volume":"20","author":"JA Stoner","year":"2010","unstructured":"Stoner JA, Leroux BG, Puumala M. Optimal combination of estimating equations in the analysis of multilevel nested correlated data. Stat Med. 2010;20(4):464\u201373. https:\/\/doi.org\/10.1002\/sim.3776.","journal-title":"Stat Med"},{"issue":"6","key":"3797_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0233595","volume":"15","author":"P Mitchell","year":"2020","unstructured":"Mitchell P, Sheidow TG, Farah ME, et al. Effectiveness and safety of ranibizumab 0.5 mg in treatment-na\u00efve patients with diabetic macular edema: results from the real-world global LUMINOUS study. PLoS ONE. 2020;15(6):e0233595. https:\/\/doi.org\/10.1371\/journal.pone.0233595.","journal-title":"PLoS One"},{"issue":"8","key":"3797_CR22","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1056\/NEJMoa2204225","volume":"25","author":"CD Jhaveri","year":"2022","unstructured":"Jhaveri CD, Glassman AR, Ferris FL 3, et al. Aflibercept monotherapy or Bevacizumab first for diabetic macular edema. N Engl J Med. 2022;25(8):692\u2013703. https:\/\/doi.org\/10.1056\/NEJMoa2204225.","journal-title":"N Engl J Med"},{"issue":"10","key":"3797_CR23","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1016\/j.ophtha.2021.03.010","volume":"128","author":"NA Malhotra","year":"2021","unstructured":"Malhotra NA, Greenlee TE, Iyer AI, Conti TF, Chen AX, Singh RP. Racial, ethnic, and insurance-based disparities upon initiation of anti-vascular endothelial growth factor therapy for diabetic macular edema in the US. Ophthalmology. 2021;128(10):1438\u201347. https:\/\/doi.org\/10.1016\/j.ophtha.2021.03.010.","journal-title":"Ophthalmology"},{"issue":"7","key":"3797_CR24","doi-asserted-by":"publisher","first-page":"380","DOI":"10.3928\/23258160-20220615-01","volume":"53","author":"TE Greenlee","year":"2022","unstructured":"Greenlee TE, Malhotra NA, Iyer AI, Conti TF, Chen AX, Singh RP. Association of socioeconomic health care disparities with use of anti-vascular endothelial growth factor and visual acuity outcomes in patients with diabetic macular edema. Ophthalmic Surg Lasers Imaging Retina. 2022;53(7):380\u201391. https:\/\/doi.org\/10.3928\/23258160-20220615-01.","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"1","key":"3797_CR25","doi-asserted-by":"publisher","first-page":"034","DOI":"10.17352\/ijcem.000027","volume":"3","author":"A Barsegian","year":"2017","unstructured":"Barsegian A, Kotlyar B, Lee J, Salifu MO, McFarlane SI. Diabetic retinopathy: focus on minority populations. Int J Clin Endocrinol Metabolism. 2017;3(1):034\u201345. https:\/\/doi.org\/10.17352\/ijcem.000027.","journal-title":"Int J Clin Endocrinol Metabolism"},{"key":"3797_CR26","doi-asserted-by":"publisher","unstructured":"Tatsumi T. Current treatments for diabetic macular edema. Int J Mol Sci. 2023;31(11):9591. https:\/\/doi.org\/10.3390\/ijms24119591.","DOI":"10.3390\/ijms24119591"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-024-03797-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-024-03797-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-024-03797-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T10:04:17Z","timestamp":1735553057000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-024-03797-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,30]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3797"],"URL":"https:\/\/doi.org\/10.1186\/s12886-024-03797-9","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,30]]},"assertion":[{"value":"29 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No human participants were included in this study. This study adheres to the Declaration of Helsinki. The study was reviewed by WCG Institutional Review Board (IRB) (Puyallup, WA) and was considered exempt from ethical approval due to using anonymized, de-identified data. Furthermore, WCG IRB waived the need for patient consent as Veran Health certified the study was conducted on anonymized, deidentified data for research purposes.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AL and MH: Employee salary; stock or stock options \u2013 Verana Health. BLK: No conflicts of interest. DT, EK, and VG: Employee salary; Stock \u2013 Genentech, Inc. RPS: Personal fees \u2013 Genentech\/Roche, Alcon, Novartis\/Gyroscope, Apellis, Zeiss, Bausch + Lomb, Regeneron Pharmaceuticals, Inc. TL: Grants\/Contracts \u2013 Astellas; Consulting fees \u2013 Alcon, Aptitude Medical, Astellas, Boehringer Ingelheim, Iridex, Nanoscope, Regeneron, Roche\/Genentech, Verana Health, Virtual Field.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"552"}}